hit counter
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock News Sentiment & Price - Sentifly
ARWR - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Arrowhead Pharmaceuticals, Inc. (ARWR)

USA
Biotechnology
NASDAQ
ARWR Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ARWR Latest news
Business Wire
Neutral
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
2021-09-01 07:30

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

Seeking Alpha
Positive
The Partnership Effect: Arrowhead Forges Its Future
2021-08-26 21:37

Arrowhead Pharmaceuticals is a leading innovator in promising drugs to treat crippling diseases. This piece focuses on its two most advanced liver disease drugs in trial, which also form the practical core of two key partnerships.

24/7 Wall Street
Neutral
Friday Afternoon Analyst Upgrades and Downgrades: Carnival, Duke Energy, Petco Health and More
2021-08-06 12:44

With the trading day more than halfway over, the broad markets were somewhat mixed.

Seeking Alpha
Neutral
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results - Earnings Call Transcript
2021-08-06 00:11

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results - Earnings Call Transcript

Benzinga
Neutral
Recap: Arrowhead Pharmaceuticals Q3 Earnings
2021-08-05 17:29

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.29), which missed the estimate of ($0.20).

Business Wire
Neutral
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
2021-07-29 07:30

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead receives breakthrough therapy designation for ARO-AAT and announces full enrollment for SEQUOIA Phase 2 clinical trial

The Motley Fool
Neutral
Arrowhead Pharmaceuticals: Buy the Dip?
2021-07-19 10:46

This biotech underdog offers more than meets the eye.

Business Wire
Neutral
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-07-14 07:30

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire
Neutral
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
2021-07-14 07:30

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results

Forbes
Positive
Will Arrowhead Stock Rebound After A Large 30% Decline Last Week?
2021-07-07 09:40

The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided to pause its early stage clinical trials for AROENaC1001, the company's investigational treatment.

Loading more news...